If you haven`t bought NVAX during the pandemic:
Then you need to know that NVAX Novavax's recent achievements in gaining full marketing authorization for its COVID-19 vaccine, Nuvaxovid, in the UK and Singapore, alongside its availability in major U.S. pharmacies, have ignited optimism among investors. These milestones signify a bright future for NVAT...
Its right at the support line and could rally towards 160. It must stay above 95, otherwise its going further down.
Its tech analysis and not any advice to buy/sell.
Following weekly chart.
- Now covid variant on the way
- Novavax vaccine is working for the new variant, if it spreads more, company is on a way to make good money.
And technically we're on a deep.
TP1 - Following EMA100 for a first target
TP2 - 80 is a nice area as a fibonacci level and a resistance.
TP3 - Planinng to hold some till 250, it reached 2 times...
Informed Players and speculators at Sub $100 levels are booking gains
we wait for additional drwadowns and re accomodation ACCUMULATION of designated Bankers for the next run up OR cycle
Vaccine COViD was intense HiV was the sell on News..
we await next Drama and Biden Policy on Healthcare etc..
for now Watch or Chrun at key leves (eyeball the box)
Moderna shows 145 or 115 as a target on the short side..
Building a very good base up here or it's preparing to break below 115 to target 80$.
Nonetheless been short since 210/share.
all gas no breaks with a full tank and a full trunk. this covid vaccine stock enjoyed a huge runup to the release of the vaccine, but since has languished on the monthly as it lost over 90% of the price high. im not looking towards this as a long term investment, but im buying the rumor that nvax is announcing new trials or a variant innoculation or at least some...
the inability of NVAX to properly capitalize on the covid vaccine is a sign of a poorly managed company. was the rise from near penny status exceptional? of course. was the following wealth destruction of epic proportions? sure was.
endless upset longs continue to exit as all good news acts as a selling event. this will be a ride back to single digits for a...
BNTX is finally concluding a year long descending triangle pattern. I see a low risk entry at $150 and will be buying. Stop loss set at $138.49, risking about 8.5%. If we see a large move upward, I could see the stock retesting both its 200 day moving average (likely at $183) and its next major resistance after that at $295. A potential of nearly 100% profit (not...
Novavax NVAX is actually lining up pretty well... from about 240, it tanked to 40, and on Friday, it gained 11% to close the week at 57.15.
This caught my attention as it cleanly broke out of trendlines, breaking out also from a bearish divergence, on BOTH the weekly and daily chart.
IMHO, it appears to be in technical and fractal alignment.
Weekly chart...
Tonix is a producer of the TNX-801 vaccine, effective against Smallpox and Monkeypox.
But that`s not all!
They have a strong balance sheet, Cash and Cash Equivalents Totaled Approximately $140 Million VS its mk cap of only $44.03Mil.
Seth Lederman, M.D., Chief Executive Officer of Tonix: “Tonix is making meaningful strides developing our rich portfolio of high...
GOVX GeoVax Labs is a biotechnology company developing immunotherapies and vaccines against infectious diseases and cancer.
GeoVax Labs will report Q1 2022 financial results on April 27.
Jason McCarthy from Maxim Group has a $10.00 price target for GOVX.
The stock is now $1.01.
Market Cap of only 7.23Mil.
This is a 4X upside potential short term stock in my opinion.
on weekly we can see bearish divergence on RSI. there is also possible h&s forming. we have also fundemantals about rigged vaccine trials for emergency authorization acceptance, vaccine deaths piling up and big shareholders of Pfizer dumping their stock.
sell now!
first profit target 32$
second profit target 1$
novavax blew up after announcing it was making a covid vaccine. they eventually parléd this into a montly uptrend that lasted until september '21. since then it has seen a major decline. the stock is attempting to end that now, or at least find a temporary rally from new multi year lows. this could lead to a short squeeze zipping the price back up towards weekly...
They have at their disposal the technical analysis of Novacyt, it has great bullish potential, they have marked resistance and support.
I hope it will help you.
Sincerely, L.E.D. In Spain on 01/20/2022
I made a personal TA on NYSE:PFE using FIB retracements to define when to buy the current pullback reversal.
PFE is currently in a very clear uptrend an its previous pullbacks "reversed" at aroung 50%-61.8% FIB so i think that this current pullback is going to reverse at around 50%.
Before buying:
Check Rsi bounceoff and SMA positionning to form a...
Analyst Vernon Bernardino from H.C. Wainwright reiterated a buy rating and $19 price target on ARDS: "the cocktail binds to the S2 spike protein subunit, which mediates viral cell membrane fusion in SARS-CoV-2 variants and also binds to the omicron variant with no loss in affinity compared to the original Wuhan strain."
Aridis Pharmaceuticals Inc 's monoclonal...
